Andrea Ellis Sells 10,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 10,000 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $35.00, for a total transaction of $350,000.00. Following the transaction, the director now directly owns 12,000 shares of the company’s stock, valued at approximately $420,000. This trade represents a 45.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Andrea Ellis also recently made the following trade(s):

• On Tuesday, April 1st, Andrea Ellis sold 30,000 shares of BridgeBio Pharma stock. The shares were sold at an average price of $34.05, for a total transaction of $1,021,500.00.

BridgeBio Pharma Stock Up 0.1 %

Shares of BBIO opened at $33.87 on Friday. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.47. The stock has a market cap of $6.44 billion, a PE ratio of -11.88 and a beta of 1.08. The firm’s fifty day moving average is $33.73 and its two-hundred day moving average is $30.01.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million for the quarter, compared to analysts’ expectations of $4.04 million. As a group, research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of BridgeBio Pharma by 6.2% in the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock valued at $413,738,000 after purchasing an additional 879,059 shares during the last quarter. Janus Henderson Group PLC increased its stake in shares of BridgeBio Pharma by 1.9% in the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock worth $134,672,000 after acquiring an additional 89,521 shares during the last quarter. Farallon Capital Management LLC raised its holdings in shares of BridgeBio Pharma by 140.1% during the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock worth $115,111,000 after acquiring an additional 2,448,000 shares during the period. Frazier Life Sciences Management L.P. boosted its position in shares of BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after acquiring an additional 40,000 shares during the last quarter. Finally, Capital Research Global Investors grew its holdings in shares of BridgeBio Pharma by 34.9% in the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after purchasing an additional 912,439 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BBIO has been the topic of several recent analyst reports. Evercore ISI increased their target price on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on BridgeBio Pharma from $44.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, March 24th. Citigroup increased their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Finally, Scotiabank boosted their price target on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $53.00.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.